Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy

Clinical trial NCT05322187 · UNKNOWN

Trial details

NCT number: NCT05322187
Sponsor: RenJi Hospital
Status: UNKNOWN
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Transitional Cell Tumor Hepatoblastoma Liver Cancer Pediatric Solid Tumor Pediatric Cancer

Start date: 2022-04-10
Primary completion: 2023-09-30
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.